Diabetes complications and comorbidities: Hyperglycemia

Semaglutide significantly improves glycemic control and reduces bodyweight in treatment-naïve patients with type 2 diabetes, results of the placebo-controlled SUSTAIN 1 trial suggest.

Results of a preclinical study confirm that microvascular destabilization caused by diabetes exacerbates cardiac ischemic damage, but this damage may be partially combated with treatment to induce neovascularization.

Glucose variability rises with increasingly insulin-dependent forms of diabetes, report researchers.

Canagliflozin improves glycemic variability and treatment satisfaction in patients with type 1 diabetes using the sodium glucose cotransporter 2 inhibitor as an add-on to insulin, show findings from a randomized trial.

Researchers believe that guidelines for Type 2 diabetes should specify that exercise should be taken after eating, especially if the meal contains a lot of carbohydrate.

Accounting for the age of red blood cells strengthens the association between glycated haemoglobin and glucose levels, improving estimates of glycaemic control in patients with diabetes, a study shows.

A safety study finds that hyperglycaemia is the most common adverse event in patients with Type 1 diabetes using a closed-loop insulin delivery system on an outpatient basis.

The IN CONTROL trial demonstrates that continuous glucose monitoring improves glycaemic control in Type 1 diabetes patients who have hypoglycaemia unawareness.

Customised approaches that specifically address barriers to care result in improved metabolic control in patients with Type 2 diabetes, shows the DROP A1C study.